SLC45A3

Solute carrier family 45 member 3 (SLC45A3), also known as prostate cancer-associated protein 6 or prostein, is a protein that in humans is encoded by the SLC45A3 gene.[5][6][7]

SLC45A3
Identifiers
Aliases	SLC45A3, IPCA-2, IPCA-6, IPCA-8, IPCA6, PCANAP2, PCANAP6, PCANAP8, PRST, solute carrier family 45 member 3
External IDs	OMIM: 605097 MGI: 1922082 HomoloGene: 23813 GeneCards: SLC45A3
Gene location (Human) Chr. Chromosome 1 (human)[1] Band 1q32.1 Start 205,657,851 bp[1] End 205,680,509 bp[1]
Gene location (Mouse) Chr. Chromosome 1 (mouse)[2] Band 1|1 E4 Start 131,962,967 bp[2] End 131,982,969 bp[2]
Gene ontology Molecular function • sucrose:proton symporter activity • sugar transmembrane transporter activity Cellular component • integral component of membrane • membrane • cell membrane Biological process • transmembrane transport • sucrose transport • positive regulation of glucose metabolic process • positive regulation of fatty acid biosynthetic process • regulation of oligodendrocyte differentiation • hexose transport Sources:Amigo / QuickGO
Orthologs
Species	Human	Mouse
Entrez	85414	212980
Ensembl	ENSG00000158715	ENSMUSG00000026435
UniProt	Q96JT2	Q8K0H7
RefSeq (mRNA)	NM_033102	NM_001177628 NM_145977
RefSeq (protein)	NP_149093	NP_001171099 NP_666089
Location (UCSC)	Chr 1: 205.66 – 205.68 Mb	Chr 1: 131.96 – 131.98 Mb
PubMed search	[3]	[4]
Wikidata
View/Edit Human View/Edit Mouse

SLC45A3 is expressed in a prostate-specific manner by normal tissues and at a significantly lower level in prostate tumor cell lines. Treatment of prostate cancer cell lines with androgens upregulates the expression of SLC45A3.[7]

Regulation

There is evidence that the expression of SLC45A3 is regulated by the microRNA mir-126*.[8]

References

1. GRCh38: Ensembl release 89: ENSG00000158715 - Ensembl, May 2017
2. GRCm38: Ensembl release 89: ENSMUSG00000026435 - Ensembl, May 2017
3. "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
4. "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
5. "Entrez Gene: solute carrier family 45".
6. Walker MG; Volkmuth W; Sprinzak E; Hodgson D; Klingler T (December 1999). "Prediction of gene function by genome-scale expression analysis: prostate cancer-associated genes". Genome Res. 9 (12): 1198–203. doi:10.1101/gr.9.12.1198. PMC 310991. PMID 10613842.
7. Xu J; Kalos M; Stolk JA; Zasloff EJ; Zhang X; Houghton RL; Filho AM; Nolasco M; Badaró R; Reed SG (February 2001). "Identification and characterization of prostein, a novel prostate-specific protein". Cancer Res. 61 (4): 1563–8. PMID 11245466.
8. Musiyenko A; Bitko V; Barik S (2008). "Ectopic expression of miR-126*, an intronic product of the vascular endothelial EGF-like 7 gene, regulates prostein translation and invasiveness of prostate cancer LNCaP cells". J Mol Med. 86 (3): 313–22. doi:10.1007/s00109-007-0296-9. PMC 3263384. PMID 18193184.

Further reading

• Pflueger D, Rickman DS, Sboner A, et al. (2009). "N-myc downstream regulated gene 1 (NDRG1) is fused to ERG in prostate cancer". Neoplasia. 11 (8): 804–11. doi:10.1593/neo.09572. PMC 2713587. PMID 19649210.
• Helgeson BE, Tomlins SA, Shah N, et al. (2008). "Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer". Cancer Res. 68 (1): 73–80. doi:10.1158/0008-5472.CAN-07-5352. PMID 18172298.
• Gerhard DS, Wagner L, Feingold EA, et al. (2004). "The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC)". Genome Res. 14 (10B): 2121–7. doi:10.1101/gr.2596504. PMC 528928. PMID 15489334.
• Esgueva R, Perner S, J LaFargue C, et al. (2010). "Prevalence of TMPRSS2-ERG and SLC45A3-ERG gene fusions in a large prostatectomy cohort". Mod. Pathol. 23 (4): 539–46. doi:10.1038/modpathol.2009.193. PMC 2848699. PMID 20118910.
• Strausberg RL, Feingold EA, Grouse LH, et al. (2002). "Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences". Proc. Natl. Acad. Sci. U.S.A. 99 (26): 16899–903. doi:10.1073/pnas.242603899. PMC 139241. PMID 12477932.
• Kimura K, Wakamatsu A, Suzuki Y, et al. (2006). "Diversification of transcriptional modulation: large-scale identification and characterization of putative alternative promoters of human genes". Genome Res. 16 (1): 55–65. doi:10.1101/gr.4039406. PMC 1356129. PMID 16344560.
• Friedman RS; Spies AG; Kalos M (2004). "Identification of naturally processed CD8 T cell epitopes from prostein, a prostate tissue-specific vaccine candidate". Eur. J. Immunol. 34 (4): 1091–101. doi:10.1002/eji.200324768. PMID 15048720.
• Maher CA, Kumar-Sinha C, Cao X, et al. (2009). "Transcriptome sequencing to detect gene fusions in cancer". Nature. 458 (7234): 97–101. doi:10.1038/nature07638. PMC 2725402. PMID 19136943.
• Musiyenko A; Bitko V; Barik S (2008). "Ectopic expression of miR-126*, an intronic product of the vascular endothelial EGF-like 7 gene, regulates prostein translation and invasiveness of prostate cancer LNCaP cells". J. Mol. Med. 86 (3): 313–22. doi:10.1007/s00109-007-0296-9. PMC 3263384. PMID 18193184.
• Kiessling A; Stevanovic S; Füssel S; Weigle B; Rieger MA; Temme A; Rieber EP; Schmitz M (March 2004). "Identification of an HLA-A*0201-restricted T-cell epitope derived from the prostate cancer-associated protein prostein". Br. J. Cancer. 90 (5): 1034–40. doi:10.1038/sj.bjc.6601642. PMC 2410218. PMID 14997204.
• Satake W, Nakabayashi Y, Mizuta I, et al. (2009). "Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease". Nat. Genet. 41 (12): 1303–7. doi:10.1038/ng.485. PMID 19915576.
• Kalos M, Askaa J, Hylander BL, et al. (2004). "Prostein expression is highly restricted to normal and malignant prostate tissues". Prostate. 60 (3): 246–56. doi:10.1002/pros.20043. PMID 15176054.
• Sheridan T; Herawi M; Epstein JI; Illei PB (2007). "The role of P501S and PSA in the diagnosis of metastatic adenocarcinoma of the prostate". Am. J. Surg. Pathol. 31 (9): 1351–5. doi:10.1097/PAS.0b013e3180536678. PMID 17721190.